Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy
BRAF/MEK 抑制剂联合疗法可靶向治疗同时存在 BRAF 非 p.V600 和 NF1 功能丧失突变的黑色素瘤
期刊:Cell Reports
影响因子:7.5
doi:10.1016/j.celrep.2022.110634
Shivshankari Rajkumar, Diana Berry, Kayla A Heney, Colton Strong, LeeAnn Ramsay, Mathieu Lajoie, Rached Alkallas, Tan-Trieu Nguyen, Cameron Thomson, Mozhdeh Ahanfeshar-Adams, Matthew Dankner, Teresa Petrella, April A N Rose, Peter M Siegel, Ian R Watson
